{"type":"analysis","id":"analysis:research-isomorphic-labs-reported-40-50b-raise-is-unconfirmed-early-talk-not-a-deal","slug":"research-isomorphic-labs-reported-40-50b-raise-is-unconfirmed-early-talk-not-a-deal","title":"Isomorphic Labs' reported $40–50B raise is unconfirmed early talk, not a deal","description":"A single Bloomberg report, citing unnamed people, says the Alphabet-owned drug-discovery company is in early talks at a valuation of at least $40 billion, possibly $50 billion. Neither Isomorphic nor Alphabet has confirmed it, and the round size and investors are unknown.","published_at":"2026-10-22T04:00:00.000Z","updated_at":"2026-10-22T04:00:00.000Z","record_date":"2026-10-22","topics":["design","tools","research"],"source_urls":["https://finance.yahoo.com/healthcare/articles/alphabet-isomorphic-labs-funding-talks-040000989.html","https://siliconangle.com/2026/10/08/alphabet-spinoff-isomorphic-labs-reportedly-raising-funding-at-up-to-50b-valuation/","https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round","https://www.thecaptable.co.uk/article/isomorphic-labs-in-early-talks-to-raise-at-up-to-50bn-almost-triple-its-17-5bn-valuation-five-months-ago"],"language":"en","routes":{"html":"https://newruntime.com/analysis/research-isomorphic-labs-reported-40-50b-raise-is-unconfirmed-early-talk-not-a-deal/","markdown":"https://newruntime.com/analysis/research-isomorphic-labs-reported-40-50b-raise-is-unconfirmed-early-talk-not-a-deal.md","json":"https://newruntime.com/analysis/research-isomorphic-labs-reported-40-50b-raise-is-unconfirmed-early-talk-not-a-deal.json"},"author":{"role":"author","name":"Andrey Reshetnikov","profile":"https://newruntime.com/owner-profile.md","profile_json":"https://newruntime.com/owner-profile.json","same_as":["https://www.linkedin.com/in/reshetnikov1/","https://t.me/lapetuse"]},"editorial_provenance":{"desk":"authorial","target_ref":"deep_research:f466562a-9170-482e-913f-66be30ee7ff1","authorial_article_id":"f466562a-9170-482e-913f-66be30ee7ff1"},"next_reads":[{"type":"topic","path":"/topics/design/","url":"https://newruntime.com/topics/design/","title":"Design","reason":"Explore the design topic hub.","media_type":"text/html","markdown_url":"https://newruntime.com/topics/design.md","json_url":"https://newruntime.com/topics/design.json"},{"type":"topic","path":"/topics/tools/","url":"https://newruntime.com/topics/tools/","title":"Tools","reason":"Explore the tools topic hub.","media_type":"text/html","markdown_url":"https://newruntime.com/topics/tools.md","json_url":"https://newruntime.com/topics/tools.json"},{"type":"topic","path":"/topics/research/","url":"https://newruntime.com/topics/research/","title":"Research","reason":"Explore the research topic hub.","media_type":"text/html","markdown_url":"https://newruntime.com/topics/research.md","json_url":"https://newruntime.com/topics/research.json"},{"type":"collection","path":"/analysis/","url":"https://newruntime.com/analysis/","title":"Analysis","reason":"Open the latest authorial analysis.","media_type":"text/html","json_url":"https://newruntime.com/analysis.json"},{"type":"collection","path":"/source-ledger.json","url":"https://newruntime.com/source-ledger.json","title":"Source Ledger","reason":"Inspect the public source evidence graph.","media_type":"application/json"}]}